U.S. markets closed
  • S&P Futures

    3,832.00
    -7.00 (-0.18%)
     
  • Dow Futures

    31,498.00
    +33.00 (+0.10%)
     
  • Nasdaq Futures

    12,558.50
    -105.25 (-0.83%)
     
  • Russell 2000 Futures

    2,193.80
    +4.10 (+0.19%)
     
  • Crude Oil

    67.51
    +1.42 (+2.15%)
     
  • Gold

    1,702.60
    +4.10 (+0.24%)
     
  • Silver

    25.68
    +0.39 (+1.55%)
     
  • EUR/USD

    1.1908
    -0.0017 (-0.14%)
     
  • 10-Yr Bond

    1.5540
    +0.0040 (+0.26%)
     
  • Vix

    24.66
    -3.91 (-13.69%)
     
  • GBP/USD

    1.3822
    -0.0006 (-0.04%)
     
  • USD/JPY

    108.3820
    0.0000 (0.00%)
     
  • BTC-USD

    50,412.29
    +740.17 (+1.49%)
     
  • CMC Crypto 200

    1,019.80
    +76.63 (+8.12%)
     
  • FTSE 100

    6,630.52
    -20.36 (-0.31%)
     
  • Nikkei 225

    28,763.82
    -100.50 (-0.35%)
     

Shockwave Medical to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference

  • Oops!
    Something went wrong.
    Please try again later.
Shockwave Medical, Inc.
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

SANTA CLARA, Calif., Nov. 18, 2020 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, announced today that it will be participating in the Piper Sandler 32nd Annual Virtual Healthcare Conference, scheduled to be held December 1 to 3, 2020.

Shockwave's management is scheduled for a live fireside chat on Wednesday, December 2, 2020, at 8:30 a.m. Eastern Time. Interested parties may access a live and archived webcast of the event on the "Investors" section of the company’s website at https://ir.shockwavemedical.com.

About Shockwave Medical, Inc.

Shockwave Medical is focused on developing and commercializing products intended to transform the way calcified cardiovascular disease is treated. The company aims to establish a new standard of care for the interventional treatment of atherosclerotic cardiovascular disease through differentiated and proprietary local delivery of sonic pressure waves for the treatment of calcified plaque, which the company refers to as Intravascular Lithotripsy (IVL). IVL is a minimally invasive, easy-to-use and safe way to significantly improve patient outcomes. To view an animation of the IVL procedure and for more information, visit www.shockwavemedical.com.

Media Contact:
Scott Shadiow
+1.317.432.9210
sshadiow@shockwavemedical.com

Investor Contact:
Debbie Kaster
investors@shockwavemedical.com